Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study Export

@article{citeulike:4080614, abstract = {Analysis of gene expression data suggests that breast cancers are divisible into molecular subtypes which have distinct clinical features. This study evaluates whether pathologic features and etiologic associations differ among molecular subtypes. We evaluated 804 women with invasive breast cancers and 2,502 controls participating in a Polish Breast Cancer Study. Immunohistochemical stains for estrogen receptor {alpha}, progesterone receptor, human epidermal growth factor receptors (HER2 and HER1), and cytokeratin 5 were used to classify cases into five molecular subtypes: luminal A, luminal B, HER2-expresing, basal-like, and unclassified. Relative risks were estimated using adjusted odds ratios and 95\% confidence intervals. We observed that compared with the predominant luminal A tumors (69\%), other subtypes were associated with unfavorable clinical features at diagnosis, especially HER2-expressing (8\%) and basal-like (12\%) tumors. Increasing body mass index significantly reduced the risk of luminal A tumors among premenopausal women (odds ratios, 0.71; 95\% confidence intervals, 0.57-0.88 per five-unit increase), whereas it did not reduce risk for basal-like tumors (1.18; 0.86-1.64; Pheterogeneity = 0.003). On the other hand, reduced risk associated with increasing age at menarche was stronger for basal-like (0.78; 0.68-0.89 per 2-year increase) than luminal A tumors (0.90; 0.95-1.08; Pheterogeneity = 0.0009). Although family history increased risk for all subtypes (except for unclassified tumors), the magnitude of the relative risk was highest for basal-like tumors. Results from this study have shown that breast cancer risk factors may vary by molecular subtypes identified in expression studies, suggesting etiologic, in addition to clinical, heterogeneity of breast cancer. (Cancer Epidemiol Biomarkers Prev 2007;16(3):439-43) 10.1158/1055-9965.EPI-06-0806}, author = {Yang, Xiaohong R. and Sherman, Mark E. and Rimm, David L. and Lissowska, Jolanta and Brinton, Louise A. and Peplonska, Beata and Hewitt, Stephen M. and Anderson, William F. and Szeszenia-Dabrowska, Neonila and Bardin-Mikolajczak, Alicja and Zatonski, Witold and Cartun, Richard and Mandich, Daniza and Rymkiewicz, Grzegorz and Ligaj, Marcin and Lukaszek, Stanislaw and Kordek, Radzisaw and Garcia-Closas, Montserrat}, citeulike-article-id = {4080614}, citeulike-linkout-0 = {http://dx.doi.org/10.1158/1055-9965.EPI-06-0806}, citeulike-linkout-1 = {http://cebp.aacrjournals.org/cgi/content/abstract/16/3/439}, citeulike-linkout-2 = {http://view.ncbi.nlm.nih.gov/pubmed/17372238}, citeulike-linkout-3 = {http://www.hubmed.org/display.cgi?uids=17372238}, day = {1}, doi = {10.1158/1055-9965.EPI-06-0806}, journal = {Cancer Epidemiol Biomarkers Prev}, keywords = {background, breast, cancer, differences, etiology, molecular, risk-factors, subtypes, thelist}, month = {March}, number = {3}, pages = {439--443}, posted-at = {2009-02-23 00:41:04}, priority = {2}, title = {Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study}, url = {http://dx.doi.org/10.1158/1055-9965.EPI-06-0806}, volume = {16}, year = {2007} }

TY - JOUR ID - citeulike:4080614 L3 - citeulike-article-id:4080614 N2 - Analysis of gene expression data suggests that breast cancers are divisible into molecular subtypes which have distinct clinical features. This study evaluates whether pathologic features and etiologic associations differ among molecular subtypes. We evaluated 804 women with invasive breast cancers and 2,502 controls participating in a Polish Breast Cancer Study. Immunohistochemical stains for estrogen receptor {alpha}, progesterone receptor, human epidermal growth factor receptors (HER2 and HER1), and cytokeratin 5 were used to classify cases into five molecular subtypes: luminal A, luminal B, HER2-expresing, basal-like, and unclassified. Relative risks were estimated using adjusted odds ratios and 95% confidence intervals. We observed that compared with the predominant luminal A tumors (69%), other subtypes were associated with unfavorable clinical features at diagnosis, especially HER2-expressing (8%) and basal-like (12%) tumors. Increasing body mass index significantly reduced the risk of luminal A tumors among premenopausal women (odds ratios, 0.71; 95% confidence intervals, 0.57-0.88 per five-unit increase), whereas it did not reduce risk for basal-like tumors (1.18; 0.86-1.64; Pheterogeneity = 0.003). On the other hand, reduced risk associated with increasing age at menarche was stronger for basal-like (0.78; 0.68-0.89 per 2-year increase) than luminal A tumors (0.90; 0.95-1.08; Pheterogeneity = 0.0009). Although family history increased risk for all subtypes (except for unclassified tumors), the magnitude of the relative risk was highest for basal-like tumors. Results from this study have shown that breast cancer risk factors may vary by molecular subtypes identified in expression studies, suggesting etiologic, in addition to clinical, heterogeneity of breast cancer. (Cancer Epidemiol Biomarkers Prev 2007;16(3):439-43) 10.1158/1055-9965.EPI-06-0806 IS - 3 JF - Cancer Epidemiol Biomarkers Prev EP - 443 TI - Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study VL - 16 SP - 439 KW - background KW - breast KW - cancer KW - differences KW - etiology KW - molecular KW - risk-factors KW - subtypes KW - thelist AU - Yang, Xiaohong AU - Sherman, Mark AU - Rimm, David AU - Lissowska, Jolanta AU - Brinton, Louise AU - Peplonska, Beata AU - Hewitt, Stephen AU - Anderson, William AU - Szeszenia-Dabrowska, Neonila AU - Bardin-Mikolajczak, Alicja AU - Zatonski, Witold AU - Cartun, Richard AU - Mandich, Daniza AU - Rymkiewicz, Grzegorz AU - Ligaj, Marcin AU - Lukaszek, Stanislaw AU - Kordek, Radzisaw AU - Garcia-Closas, Montserrat PY - 2007/03/01/ UR - http://dx.doi.org/10.1158/1055-9965.EPI-06-0806 ER -